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ABSTRACT: Background. The purpose of this study was to evaluate the
predictive value of positron emission tomography (PET)-CT in identifying
occult nodal metastasis in clinically and radiographically N0 patients
with recurrent laryngeal cancer undergoing salvage laryngectomy.
Methods. Retrospective review of 46 clinically and radiographically N0
patients with recurrent laryngeal cancer who underwent a PET-CT exam-
ination before salvage laryngectomy with neck dissection from January
1, 2002, to December 31, 2014, was performed.
Results. Two patients (16.7%) had true-positive PET-CT results, whereas
10 patients (83.3%) had false-negative scans, 1 patient (2.9%) had
a false-positive result and 33 patients (97.1%) had a true-negative
PET-CT. The sensitivity of PET-CT was 16.7% (95% confidence interval
[CI], 3.5% to 46.0%) with a specificity of 97.1% (95% CI, 83.8% to 99.9%),
positive predictive value (PPV) of 66.7% (95% CI, 20.2% to 94.4%), and
negative predictive value (NPV) of 76.7% (95% CI, 62.1% to 87.0%).
Conclusion. PET-CT has poor sensitivity and NPV making PET-CT an
imperfect predictor of nodal disease in recurrent laryngeal cancer.VC 2017
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gectomy, laryngeal squamous cell carcinoma, occult nodal metasta-
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INTRODUCTION
Currently, laryngeal squamous cell carcinoma (SCC) is
routinely treated with radiotherapy (RT) or concurrent che-
moradiotherapy (CRT).1–5 This approach has been adopted
with the goal of maintaining speech and swallowing
function while providing similar survival rates compared to
primary surgery. Unfortunately, many of these patients
develop recurrences and require salvage laryngectomy.6–8
The role of neck dissection during salvage laryngectomy
is controversial. The management of patients with clinically
apparent nodal disease is straightforward, however, there is
no consensus regarding management of the clinically N0
neck. Additionally, neck dissection adds morbidity to total
laryngectomy and is associated with a higher complication
rate, including a higher rate of pharyngocutaneous fistula.9
The prevalence of occult nodal metastases in the N0 neck in
recurrent laryngeal cancer has been reported to be from 4% to
20%.9–13 Supraglottic tumors and advanced T classification
tumors have been associated with an even higher occult nodal
metastasis rate.11–13 When taken together, patients with T4
supraglottic tumors have a 50% risk of occult nodal disease.13
Efforts have been made to predict the likelihood of nodal
metastases in these patients. The staging of the neck before
initial therapy has been shown to correlate with the risk of
occult nodal disease in neck dissection specimens.11
Preoperative CT and MRI scans have been used to
improve preoperative staging, however, these tests
have poor sensitivity leading to an inadequate negative
predictive value (NPV).14–16
The 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG) pos-
itron emission tomography (PET), in combination with CT
(PET-CT), is increasingly being used in the management of
patients with head and neck cancer, including initial stag-
ing, assessing response to therapy, detecting recurrence,
and identifying unknown primary tumors.15,17–29 Addition-
ally, PET-CT is increasingly used to improve the accuracy
of staging in recurrent laryngeal cancer.30 Although the
ability of PET-CT to detect nodal metastasis in other tumors
has been addressed, the predictive value of PET-CT in
detecting nodal disease in patients with recurrent laryngeal
cancer has not been well studied.15,16,21,29–37 The purpose
of this study was to evaluate the predictive value of PET-
CT in identifying nodal metastasis in patients with recurrent
laryngeal carcinoma with a clinically and radiographically
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N0 neck. The overall goal was to assess the ability of PET-
CT to discriminate the need for elective neck dissection.
MATERIALS AND METHODS
A retrospective review was performed of a cohort of
patients who underwent salvage laryngectomy with neck
dissection without clinical or radiographic (CT or MRI)
evidence of nodal disease at the University of Michigan
from January 1, 2002, to December 31, 2014. All patients
had a PET-CT before surgery. Salvage laryngectomy was
defined as surgery for persistent or recurrent laryngeal
SCC after initial RT or CRT. Patients were excluded if
they had evidence of nodal disease on clinical examina-
tion or preoperative CT or MRI. Forty-six patients met
inclusion criteria. Clinical and pathologic data were col-
lected, including initial stage and treatment of the primary
tumor as well as the staging of the recurrent or persistent
tumor. Disease was staged based on the seventh edition
of the American Joint Committee on Cancer staging
system.
Patients who underwent a PET-CT at the University of
Michigan (91.3%; 42 of 46 patients) and those who had a
PET-CT at an outside institution (8.7%; 4 of 46 patients)
were included in this study. The PET-CT was performed
per institutional protocol. At the University of Michigan,
patients were fasted for >4 to 6 hours and had glucose
levels <250 mg/dL before imaging. Around 60 minutes
after intravenous administration of 300 MBq (8 mCi) of
FDG, sequential PET and CT imaging was performed on
an integrated PET-CT scanner (Siemens Biograph T6;
Siemens Medical Solutions, Hoffman Estates, IL). Helical
CT from the skull vertex to the mid-thigh was performed
with 5-mm collimation (low-dose CT parameters: 140
kV, 80 mA, tube rotation of 0.8 second per rotation, and
pitch of 3:1), followed immediately by whole body PET
at multiple overlapping bed positions (area covered: skull
vertex to mid-thigh, step-and-shoot mode, 3 minutes per
bed position). Then, a dedicated contrast-enhanced head
and neck CT was performed with field of view 15 cm,
commencing 40 seconds after intravenous injection of
100 ml volume of iopromide (Ultravist) at 1.5 ml/second,
and coregistered to the whole body FDG PET dataset.
Images were reviewed on a workstation (MedImage;
MedView Pty, Canton, MI) by 2 readers (1 head and
neck radiologist and 1 nuclear medicine physician) pro-
viding a single read per study.
Four of the PET-CT studies were performed at outside
centers, with the imaging data transferred from compact
disc to our local archive for review. This led to some het-
erogeneity in the imaging protocols used, as some outside
centers performed dedicated head and neck PET-CT
images acquired separately (in addition to the whole body
PET-CT), whereas others performed only a whole body
PET-CT (with a large field of view). Evidence of PET-
CT positivity was determined by the official report of the
reading radiologist at the time of the scan, on which
patients’ management was based. In addition, PET-CT
images were reviewed by a single reader (author K.K.W.,
board certified in Nuclear Medicine) who was blinded to
the results of the official report and final pathology, with
interpretation compared with the initial clinical reads.
There were no discrepancies between the official reports
and the review by author K.K.W.
Cervical lymph nodes displaying FDG uptake above
background were considered either suspicious or positive
for regional nodal metastasis. PET-CT results were catego-
rized as positive or negative. All nodes that were considered
suspicious by the reading radiologist were categorized as
positive. Final pathology results were collected and the nod-
al metastases were tabulated. For patients who underwent a
unilateral neck dissection, only the dissected neck was
included in the analysis.
Patient population
Forty-six patients, 84.8% (39/46) men and 15.2% (7/46)
women with a mean age of 62.1 6 9.7 years were included
in our cohort. At the time of salvage surgery, 41.3% of
patients (19/46) were current smokers and 58.7% (27/46)
were former smokers. At the time of initial therapy, 47.8%
of tumors (22/46) were located in the supraglottis, whereas
52.2% (24/46) were located in the glottis. The neck was ini-
tially staged as N0 in 71.1% of patients (32/45), N1 in
13.3% of patients (6/45), N2b in 6.7% of patients (3/45),
and N2c in 8.9% of patients (4/45). The initial staging was
missing in 1 patient who was previously treated at an out-
side institution. Of the patients, 41.3% (19/46) were initially
treated with RT, 54.3% (25/46) were treated with CRT, and
4.3% (2/46) were treated with laser excision followed by
adjuvant RT or CRT. The mean interval to recurrence was
20.4 months. Of the recurrent primary tumors, 52.2%
(24/46) were located in the supraglottis, 45.6% (21/46)
were in the glottis, and 2.2% (1/46) were centered in the
subglottis. Recurrent tumors were staged as T1 in 4.3% of
patients (2/46), T2 in 19.6% of patients (9/46), T3 in 32.6%
of patients (15/46), and T4 in 43.5% of patients (20/46).
Patient characteristics, staging, and treatment are shown in
Table 1.
Statistical analysis
In our analysis, we initially compared PET-CT positivity
to pathologic node status on a per patient basis. We subse-
quently evaluated each neck specimen separately with the
left and right sides of the neck being analyzed individually.
After analyzing the cohort as a whole, subgroup analysis
was performed by tumor subsite, T classification, and those
patients without nodal metastasis (N0) before initial treat-
ment (RT or CRT). To calculate the sensitivity and specific-
ity of PET-CT in predicting nodal metastasis, results of the
PET-CT scans were compared to the final pathology (gold
standard). Positive predictive values (PPV) and NPVs were
calculated. Ninety-five percent confidence intervals (95%
CI) were calculated using the method described by Agresti
and Coull.38 All statistical analysis was performed using
IBM SPSS software version 20 (IBM, Armonk, NY) with
consultation from the University of Michigan Center for
Statistical Consultation and Research. This study was
approved by the University of Michigan Internal Review
Board (HUM00081554).
RESULTS
In our cohort of 46 patients, 3 patients (6.5%) had a positive
PET-CT scan. Twelve patients (26.1%) were noted to have
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nodal metastasis on final pathology, with 2 true-positive
(16.6%) and 10 false-negative (83.3%) PET-CTs. Of the 34
patients without nodal metastasis on final pathology, there was
1 false-positive scan (2.9%) and 33 true-negative scans
(97.1%; Table 2) The sensitivity of PET-CT when compared
to the final pathology was 16.7% (95% CI, 3.5% to 46.0%)
and the specificity was 97.1% (95% CI, 83.8% to 99.9%). In
this cohort, the PPV was 66.7% (95% CI, 20.2% to 94.4%)
and NPV was 76.7% (95% CI, 62.1% to 87.0%).
We then evaluated the cohort looking at each neck
specimen separately. Eight patients either had a previous
unilateral neck dissection as part of their initial therapy (n
5 4) or only the ipsilateral neck was dissected (n 5 4) at
the time of salvage laryngectomy, and, thus, there were
84 neck specimens in our analysis. In total, 15 of the
neck specimens (17.8%) contained nodal metastasis, 2
(13.3%) of which were detected by PET-CT. There were
69 neck specimens without nodal disease with only 2
(3.0%) having false-positive scans. The false-positive
scans corresponded to 1 patient with a PET-CT sugges-
tive of bilateral neck disease who had no pathologic
lymph nodes on final pathology. The sensitivity of
PET-CT when compared to the final pathology was
13.3% (95% CI, 24.8% to 39.1%) and the specificity was
97.1% (95% CI, 89.4% to 99.8%). In this analysis, the
PPV was 50.0% (95% CI, 15.0% to 85.0%) and NPV was
83.8% (95% CI, 74.0% to 90.4%; Table 3).
In a subgroup analysis, we evaluated the 32 patients
classified as N0 before their initial therapy. In this group,
there were 10 patients (31.3%) with nodal metastasis on
final pathology, 2 (20.0%) of which were identified on
PET-CT with 8 false-negative scans. Of the 22 patients
without regional metastasis, there was 1 false-positive
(4.5%) and 21 true-negative (95.4%) PET-CT scans
(Table 4). The sensitivity and specificity were 20.0%
(95% CI, 4.6% to 52.1%) and 95.5% (95% CI, 76.5% to
99.9%), respectively. In this population, this corresponds
to a PPV of 66.7% (95% CI, 20.2% to 94.3%) and NPV
of 72.4% (95% CI, 54.1% to 85.5%).
We evaluated our cohort of patients who were classified as
N0 before their initial therapy looking at each neck specimen
separately. There were 58 neck specimens in our analysis.
There were 13 neck specimens (22.4%) with pathologically
confirmed nodal metastasis, 2 (15.4%) of which were identified
TABLE 2. Positron emission tomography-CT test results compared to
final pathology (gold standard) in the entire cohort.
PET-CT evidence of
nodal metastasis
Pathological nodal metastasis
Yes No
Yes 2 1
No 10 33
Abbreviation: PET, positron emission tomography.
Sensitivity 5 16.7% (95% confidence interval [CI], 3.5% to 46.0%).
Specificity5 97.1% (95% CI, 83.8% to 99.9%).
Positive predictive value 5 66.7% (95% CI, 20.2% to 94.4%).
Negative predictive value 5 76.7% (95% CI, 62.1% to 87.0%).
TABLE 3. Positron emission tomography-CT test results compared to
final pathology (gold standard) in the entire cohort when evaluating the
left and right sides of the neck separately.
PET-CT evidence of
nodal metastasis
Pathological nodal metastasis
Yes No
Yes 2 2
No 13 67
Abbreviation: PET, positron emission tomography.
Sensitivity 5 13.3% (95% confidence interval [CI], 24.8% to 39.1%).
Specificity5 97.1% (95% CI, 89.4% to 99.8%).
Positive predictive value 5 50.0% (95% CI, 15.0% to 85.0%).
Negative predictive value 5 83.8% (95% CI, 74.0% to 90.4%).
TABLE 1. Baseline characteristics of the study cohort.
Characteristic Value (n 5 46)
Age at salvage surgery, y, mean (SD) 62.1 (9.7)
Sex
Male 84.8% (39)
Female 15.2% (7)
Tobacco status at salvage
Current 41.3% (19)
Former 58.7% (27)
Never 0% (0)
Alcohol status at salvage
Current* 15.9% (7)
Former* 11.4% (5)
Never* 72.7% (32)
Missing data 3.8% (2)
Initial tumor subsite
Supraglottic 47.8% (22)
Glottic 52.2% (24)
Subglottic 0% (0)
Initial stage
I* 20.0% (9)
II* 26.7% (12)
III* 33.3% (15)
IV* 20.0% (9)
Missing data 2.2% (1)
Initial N classification
N0 71.1% (32)
N1 13.3% (6)
N2a 6.7% (3)
N2b 8.9% (4)
N2c 2.2% (1)
Missing data
Initial treatment
RT 41.3% (19)
CRT 54.3% (25)
Laser excision with RT 2.2% (1)
Laser excision with CRT 2.2% (1)
Interval to recurrence, mo, mean (SD) 20.4% (20.0)
Recurrent/persistent tumor subsite
Supraglottic 52.2% (24)
Glottic 45.6% (21)
Subglottic 2.2% (1)
Recurrence T classification
T1 4.3% (2)
T2 19.6% (9)
T3 32.6% (15)
T4 43.5% (20)
Abbreviations: RT, radiotherapy; CRT, chemoradiotherapy.
Note: Initial tumor designates the tumor characteristics and treatment before the diagnosis of
recurrence or persistence. Recurrent tumor designates that tumor treated by salvage laryn-
gectomy with neck dissection.
* Data shown as a percentage of the known conditions of the variable excluding those
patients with missing data.
ROSKO ET AL.
982 HEAD & NECK—DOI 10.1002/HED MAY 2017
on PET-CT with 11 false-negative scans. Of the 45 neck speci-
mens without pathologically positive nodes, 43 (95.6%) had a
negative PET-CTwith 2 false-positive scans (Table 5). The sen-
sitivity and specificity were 15.4% (95% CI, 3.1% to 43.4%)
and 95.6% (95% CI, 84.4% to 99.6%), respectively. The PPV
was 50.0% (95% CI, 15.0% to 85.0%) and the NPV was 79.6%
(95% CI, 66.9% to 88.4%).
In order to better understand the performance of
PET-CT, we analyzed our cohort based on the recurrent
tumor subsite and recurrent tumor T classification (Table 6).
The small size of each group limited the analysis. As
expected, the NPV was highest in patients with low risk for
nodal metastasis (T1 or T2 tumors and glottic primaries)
and was lowest in patients who were at the highest risk for
occult nodal disease (T3 and T4 tumors and supraglottic
primaries). Although the sensitivity was slightly better in
patients with T3 tumors compared with other T classifica-
tions, the differences were not statistically significant. This
was due to the small number of true-positive scans in the
cohort.
The patients who had false-negative PET-CT scans are
of particular interest. Of the 10 patients in our overall
cohort with false-negative PET-CT scans, 6 patients had
1 occult node, 1 patient had 2 occult nodes, 1 patient had
3 occult nodes, 1 patient had 7 occult nodes, and 1 patient
had 29 occult nodes that were positive for metastatic
SCC on final pathology (Table 7). Histopathologic lymph
node tissue was available for review in 5 of the 10
patients. The average size of metastatic deposit in the
lymph node was 3 mm (range, 1–7 mm). Representative
images of the PET-CT from the patient with 29 occult
nodes are shown in Figure 1 and representative images of
an occult node from this patient are shown in Figure 2.
DISCUSSION
PET-CT has proven to be a valuable tool in caring for
patients with head and neck cancer. First described by
Warburg39 in 1956, PET-CT capitalizes on the concept
that malignant cells exhibit increased glucose utilization
by upregulating glucose transporters. FDG, a radiophar-
maceutical analog of glucose, is taken up by malignant
cells and undergoes phosphorylation by hexokinase to
FDG-6-phosphate; however, unlike glucose, FDG is
trapped intracellularly as an index of the metabolic activi-
ty of tumor cells.39 This technology has proven useful in
initial staging, assessing treatment response, monitoring
for recurrence, and identifying distant metastasis in
patients with head and neck cancer.18,19,26,34,40,41
Although PET-CT has been shown to have increased
sensitivity when compared to CT or MRI, the role of
PET-CT in guiding treatment of the neck, especially in
the salvage setting, is evolving.13–15
TABLE 4. Positron emission tomography-CT test results compared to
final pathology (gold standard) in patients who were previously N0
before initial therapy.
PET-CT evidence of
nodal metastasis
Pathological nodal metastasis
Yes No
Yes 2 1
No 8 21
Abbreviation: PET, positron emission tomography.
Sensitivity 5 20.0% (95% confidence interval [CI], 4.6% to 52.1%).
Specificity 5 95.5% (95% CI, 76.5% to 99.9%).
Positive predictive value 5 66.7% (95% CI, 20.2% to 94.3%).
Negative predictive value 5 72.4% (95% CI, 54.1% to 85.5%).
TABLE 5. Positron emission tomography-CT test results compared to
final pathology (gold standard) in patients who were previously N0
before initial therapy when evaluating the left and right side of the neck
separately.
PET-CT evidence of
nodal metastasis
Pathological nodal metastasis
Yes No
Yes 2 2
No 11 43
Abbreviation: PET, positron emission tomography.
Sensitivity 5 15.4% (95% confidence interval [CI], 3.1% to 43.4%).
Specificity 5 95.6% (95% CI, 84.4% to 99.6%).
Positive predictive value 5 50.0% (95% CI, 15.0% to 85.0%).
Negative predictive value 5 79.6% (95% CI, 66.9% to 88.4%).
TABLE 6. Positron emission tomography-CT performance based on recurrent tumor subsite and T classification.
Variables
Sensitivity
(95% CI)
Specificity
(95% CI)
PPV
(95% CI)
NPV
(95% CI)
T1/T2
(n 5 11)
NA* 100%
(71.2% to 100%)
NA* 100%
(71.2% to 100%)
T3
(n 5 15)
33.3%
(56.3% to 79.8%)
100%
(71.2% to 100%)
100%
(16.8% to 100%)
85.6%
(58.8% to 97.2%)
T4
(n 5 20)
11.1%
(0.0% to 45.7%)
90.1%
(60.1% to 100%)
50.0%
(9.5% to 90.6%)
55.6%
(33.7% to 75.5%)
T3/T4
(n 5 35)
16.7%
(3.5% to 46.0%)
95.7%
(77.3% to 100%)
66.7%
(20.2% to 94.4%)
68.8%
(51.3% to 82.2%)
Supraglottis
(n 5 24)
0%
(0% to 37.2%)
100%
(77.3% to 100%)
NA† 66.7%
(46.6% to 82.2%)
Glottis
(n 5 21)
50.0%
(15.0% to 85.0%)
94.4%
(72.4% to 100%)
66.7%
(20.2% to 94.4%)
89.5%
(67.4% to 98.3%)
Abbreviations: 95% CI, 95% confidence interval; PPV, positive predictive value; NPV, negative predictive value; NA, not applicable.
* No patients with T2 tumors had positive nodes on final pathology.
† There were no positive positron emission tomography-CT scans.
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To the best of our knowledge, this is the largest study
to evaluate the ability of PET-CT to detect nodal metasta-
sis in patients with recurrent laryngeal carcinoma. In our
study of clinically and radiographically (based on CT or
MRI) N0 patients, the sensitivity of PET-CT was 16.7%
with a specificity of 97.1%. In our population, this
yielded an NPV of only 76.7%. When we compared our
results to other reports in the literature, we noted a wide
range of reported sensitivities and specificities. In these
studies, the reported sensitivity ranges from 71% to 89%
and specificity ranges from 82% to 100%.21,32,36,40,41 In
the largest meta-analysis of 1236 patients in 32 studies,
PET-CT had pooled sensitivity of 79% (95% CI, 72% to
85%) in detecting cervical nodal metastases with a specif-
icity of 86% (95% CI, 83% to 89%). Notably, PET-CT
had an even lower sensitivity of 50% (95% CI, 37% to
63%) in detecting occult nodal metastasis in the clinically
N0 patient, although it did have a reasonable specificity
of 87% (76% to 93%).42
The current study reports a sensitivity that is substantially
lower than previous reports. This is likely because of the
differences in study design. The previous studies included
patients with head and neck cancer from all subsites, with
laryngeal primaries making up a small proportion of the
population. Additionally, the previous studies included
patients who were previously untreated, whereas our study
only included patients who were previously treated with RT
or CRT. This is important as chemotherapy and radiation
alter the lymphatics with decreased vascularity of the
residual nodes. Thus, many of the pathologically positive
TABLE 7. Number of positive nodes on final pathology in patients with
false-negative positron emission tomography-CT.
Patient
number
Nodes
positive in
right side
of neck
Nodes
positive in
left side
of neck
Total
positive
nodes
Largest
metastatic
deposit, mm
1 1 0 1 MD
2 4 3 7 MD
3 20 9 29 7
4 1 1 2 1.5
5 0 1 1 MD
6 0 1 1 MD
7 NA* 1 1 1
8 1 NA* 1 1
9 NA* 3 3 MD
10 0 1 1 3
Abbreviations: MD, missing data; NA, not applicable.
* Unilateral neck dissection performed.
FIGURE 1. Representative images
from a false-negative positron
emission tomography-CT (patient
number 3 in Table 6). Final
pathology revealed 29 positive
nodes. [Color figure can be
viewed at wileyonlinelibrary.
com]
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nodes would be below the size detection limit of PET-CT
(6–8 mm), which would, in turn, limit the sensitivity.43 Per-
haps most importantly, all other studies included patients
with clinically or radiographically apparent nodes. Includ-
ing patients with known nodal metastasis would increase
the number of true-positive scans, which, in turn, would
increase the calculated sensitivity. This study design fails to
answer the question regarding the ability of PET-CT to
detect occult nodal disease. This phenomenon is demon-
strated in the meta-analysis by Kyzas et al42 as the sensitivi-
ty drops from 79% to 50% when patients with clinically
evident nodes are excluded. The current study is the only
study evaluating the utility of PET-CT to evaluate the neck
before salvage laryngectomy in a cohort of patients previ-
ously treated with CRT or RT with no clinical or radio-
graphic nodal metastasis before PET-CT. This difference in
clinical design almost certainly accounts for the difference
in sensitivity seen in our study.
The closest report to the current study was published
by Gilbert et al.31 This study consisted of a review of 15
patients with SCC of the larynx who underwent elective
neck dissection at the time of salvage laryngectomy. In
their study, they reported a sensitivity of 70% (95% CI,
39% to 90%), specificity of 100% (95% CI, 51% to
100%), and NPV of 63% (95% CI, 30% to 87%). Once
again, this study included patients with and without
clinically apparent nodal disease, which led to a higher
sensitivity than the current study, as described above.
Based on these results, the authors concluded that the
false-negative rate is too high to defer neck dissection
based solely on PET-CT results, and this conclusion is
supported in our study.30
By using the pre-test probability of occult nodal dis-
ease, the sensitivity and specificity of PET-CT from this
study can be used to calculate the PPV and NPV of a par-
ticular patient population based on previously described
methods.44 This allows the clinician to determine the
posttest probability of occult nodal disease, and it is
the posttest probability of occult disease that should drive
the decision regarding whether or not a neck dissection
should be performed. In patients with clinically apparent
nodal disease at the time of the laryngectomy, the deci-
sion to proceed with neck dissection is straightforward;
however, the decision becomes more complicated in the
previously treated neck with no evidence of disease. In
the original article by Weiss et al45 in 1994, decision
analysis was used with the conclusion that the N0 neck
should be treated if the risk of occult nodal metastasis is
greater than 20%. Ferlito et al,46 in their review of neck
dissection in laryngeal cancer, suggested that the neck
should be treated if the risk of metastasis is 15%.
Careful consideration of the risk of occult nodal disease
is important in deciding to perform a neck dissection, as
salvage laryngectomy is already associated with impaired
wound healing and wound-related complications. Further-
more, neck dissection is associated with increased mor-
bidity, including a higher fistula rate.9,47–49 Unfortunately,
there are few remaining treatment modalities available to
the patient undergoing salvage laryngectomy, and neck
dissection becomes more difficult once a laryngectomy
has been performed, especially if free tissue is used to
reconstruct the pharynx. Thus, identifying those patients
at high risk of regional failure is important. In the present
study, 26% of patients had occult cervical metastasis not
detected on either clinical examination or CT. PET-CT
failed to identify the majority of these patients, as 23% of
patients with a negative PET-CT had occult nodal
disease. Thus, based on the low sensitivity and low NPV,
PET-CT alone is an inadequate test to withhold neck
dissection.
When we considered why PET-CT had an unacceptably
low sensitivity, there was no evidence that the high rate
of false-negative scans was related to patient preparation
factors, modality of treatment (RT vs CRT), or the timing
of the PET-CT after treatment. It is believed that this was
instead related to low volume disease in the previously
treated neck with cancer deposits that were below the
spatial resolution of PET-CT leading to partial volume
effect and reduced sensitivity. On re-review of the histo-
pathology in the patients who had false-negative PET-CT
scans in our study, the average metastatic deposit was 3
mm, confirming the low volume of disease. Posttreatment
lymph nodes with limited tumor burden fall below the
detection limit of the PET-CT leading to false-negative
scans.
There were limitations to our current study. Although this
is the largest study evaluating the ability of PET-CT to
detect nodal disease before salvage laryngectomy, the sam-
ple size was still relatively small. This retrospective study
included PET-CT scans performed at our institution and
also from outside centers leading to some heterogeneity in
FIGURE 2. Representative images from the final pathology of an
occult node from a patient with a false-negative positron emis-
sion tomography (PET)-CT (patient number 3 in Table 6, PET-CT
shown in Figure 1). (A) Low powered view (original magnification
310). (B) High power view (original magnification 340). [Color
figure can be viewed at wileyonlinelibrary.com]
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the imaging protocols used. Protocols performing dedicated
head and neck PET-CT images acquired separately (in addi-
tion to the whole body PET-CT) could have improved con-
spicuity of small cervical nodes compared to protocols with
whole body PET-CT acquired over a large field of view.
However, excluding patients with outside imaging studies
did not affect our sensitivity (18.2% vs 16.7%) and specific-
ity (96.8% vs 97.1%) significantly. The retrospective nature
of this study also limits the ability to draw conclusions from
the dataset. Given these limitations, a prospective study of
PET-CT in salvage laryngectomy is needed to fully address
this question.
CONCLUSION
This study demonstrates that although PET-CT has a rea-
sonable specificity and PPV, it has inadequate sensitivity and
NPV. Based on these results, neck dissection should not be
withheld solely on the basis of a negative PET-CT when per-
forming salvage laryngectomy for recurrent laryngeal SCC.
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